Search

Search Constraints

You searched for: Author/Creator Gatselis, Nikolaos

Search Results

1. Correction: DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Issue 8 (November 2018)

2. DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B. Issue 8 (November 2018)

3. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. (October 2021)

4. Evolution of epidemiological characteristics of infective endocarditis in Greece. (May 2021)

5. Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study. (20th December 2021)

6. HERACLIS‐TAF: a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. Issue 4 (23rd June 2022)

7. Significance of serum HBV RNA in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients who discontinue effective antiviral therapy. Issue 11 (30th August 2022)

8. Temporal trends in stroke incidence and case-fatality rates in Arcadia, Greece: A sequential, prospective, population-based study. Issue 1 (January 2022)

9. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Issue 5 (11th October 2017)

10. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Issue 5 (11th October 2017)